Health
China Sinopharm’s potential COVID-19 vaccine triggers antibodies in clinical trials: journal – Reuters
A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
BEIJING (Reuters) – A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
The candidate has already moved into a late-stage trial, one of a handful of candidates being tested on several thousand people to see if they are effective enough to win regulatory approval.
Sinopharm is testing the potential vaccine in the United Arab Emir…
-
Noosa News23 hours agoBrisbane doctor jailed for trafficking ‘breathtaking amount’ of drugs
-
Business14 hours ago10 ASX shares to buy after the market selloff
-
General17 hours ago‘We are here for you’: PM to bring help to flood zones
-
General16 hours agoWe’ve all talked about potential economic consequences for Australia of Trump’s policies. Now they’re happening